you are on to something here, this company has a medical product with no comparison. They initially forecast the US market alone to be worth close to $1 billion a year and they are substantially growing revenues each quarter. I believe the recent sell of was due to the last quarterly report showing no revenue growth, but this should change with the US equivalent of Medicare substantially increasing their funding for Sirtex's product, making it more affordable for patients.
Sirtex has been distracted over the last year by events such as the takeover but I believe they will perform strongly during 2004.
oversold?, page-4
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.70M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $6.597K | 37.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 5847101 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 237659 | 23 |
View Market Depth
| Last trade - 14.58pm 27/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |